Dexmedetomidine Use in Small Animal Practice

Dexmedetomidine is a selective α2-adrenoceptor agonist with a well-established evidence base in small animal practice. Yet, despite the strong evidence supporting its use in small animal practice, dexmedetomidine is a drug that polarizes clinicians; it is routinely incorporated into some protocols and largely absent from others.

Mode of Action

Dexmedetomidine is the dextro-enantiomer of medetomidine and represents the biologically active component of the racemic mixture. It is a highly selective α2-adrenoceptor agonist with an α2:α1 selectivity ratio of approximately 1620:1, although α2-associated cardiovascular effects remain apparent. Within the central nervous system (CNS), dexmedetomidine acts at presynaptic and postsynaptic α2-adrenoceptors; peripherally, it binds to extrasynaptic receptors. Sedation is primarily mediated through presynaptic α2-receptor activation in the locus coeruleus of the pons, resulting in reduced norepinephrine release and decreased arousal. Analgesia is thought to arise predominantly from receptor binding within the dorsal horn of the spinal cord.

Pharmacokinetics

The pharmacokinetic profile of dexmedetomidine varies by route of administration, affecting onset, bioavailability, and duration of effect. Intravenous and intramuscular administration provide rapid, predictable absorption; transmucosal administration in dogs is associated with lower bioavailability and requires higher doses to achieve clinically relevant sedation. Dexmedetomidine undergoes extensive hepatic metabolism; it is eliminated primarily via renal excretion of metabolites. The elimination half-life ranges from 11.5 to 41.5 minutes in dogs and a reported 30.3 to 39.7 minutes in cats. Patients with significant hepatic impairment may experience prolonged sedation and recovery and warrant close monitoring.

Pharmacodynamics

Through activation of central and peripheral α2-adrenoceptors, dexmedetomidine produces dose-dependent effects across multiple physiologic systems. CNS effects include reduced arousal and cortical activity, producing dose-dependent sedation and anxiolysis, with analgesic effects arising primarily from modulation of nociceptive transmission at the dorsal horn of the spinal cord. Cardiovascular responses are biphasic, with initial increases in systemic vascular resistance causing reflex bradycardia, followed by persistent bradycardia, reduced cardiac output, and normotension or hypotension as sympatholytic effects predominate. Respiratory rate and minute ventilation are mildly reduced, and clinically significant respiratory depression at recommended doses is uncommon. Dexmedetomidine inhibits insulin secretion, resulting in hyperglycemia, and diuresis may occur secondary to inhibition of antidiuretic hormone release. It also impairs thermoregulatory responses, increasing the risk for hypothermia, particularly during prolonged sedation or anesthesia. Nausea and vomiting may occur, particularly after intramuscular administration.

Formulations and Routes of Administration

Dexmedetomidine is available in several formulations and can be administered via multiple routes: intravenous, intramuscular, transmucosal, subcutaneous, and intranasal. Formulations include multidose injectable solutions, 0.1 mg/mL solutions, 0.5 mg/mL solutions, preservative-free single-use vials (0.1 mg/mL), and oral transmucosal gel (Sileo, 0.1 mg/mL, indicated for at-home anxiolysis in dogs).

Clinical Considerations

Transmucosal administration in dogs results in low bioavailability, requiring higher doses (approximately 15 to 40 µg/kg) to achieve moderate to profound sedation. Transmucosal administration in cats (20 to 40 µg/kg) combined with buprenorphine (20 µg/kg) provides effective sedation. Transmucosal administration is particularly advantageous in fractious or aggressive dogs due to its minimally invasive nature and ease of administration. Sileo is licensed for use in healthy dogs to reduce noise-associated anxiety and has demonstrated efficacy for reducing fear-related behaviors during events (e.g., fireworks).

**Procedural Sedation**

Dexmedetomidine produces dose-dependent sedation that can be tailored to the requirements of the procedure and individual patient, ranging from mild sedation for low-stress handling and minor diagnostics to deep sedation for more invasive procedures. A ceiling effect exists whereby sedation depth plateaus beyond a certain dose threshold while cardiovascular effects continue to increase, reinforcing the importance of using the lowest effective dose. Combining dexmedetomidine with an opioid enhances sedation and analgesia in a synergistic manner, enabling lower doses and more predictable clinical effects.

**Take-Home Points**

• Dexmedetomidine provides reliable, dose-dependent, reversible sedation.
• Dexmedetomidine can be administered as a sole agent, but its sedative and analgesic effects are potentiated and more reliable with coadministration of opioids.
• Dexmedetomidine causes dose-dependent biphasic cardiovascular effects that lead to reduced cardiac output; use in patients with cardiac disease or hemodynamic instability is generally discouraged.
• Unless accompanied by hypotension, bradycardia caused by dexmedetomidine does not routinely warrant reversal.
• Dexmedetomidine may be administered via multiple routes as part of a balanced sedation or multimodal analgesic plan.

Dexmedetomidine is a highly selective α2-adrenoceptor agonist with a well-established role in small animal veterinary practice; it provides reliable sedation, analgesia, and the practical advantage of reversibility. Regardless, its use remains inconsistent; some clinicians avoid it due to unfamiliarity or concern about cardiovascular side effects. However, for clinicians who understand its pharmacology, appropriate patient selection, and physiologic monitoring, dexmedetomidine is a genuinely versatile and valuable addition to the small animal formulary.

This article describes the risks and benefits of using dexmedetomidine with the aim of supporting confident, evidence-based decisions.